Last reviewed · How we verify
Neurocrine UK Limited — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
1 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cortef | Cortef | marketed | Other | |||
| Infacort® | Infacort® | phase 3 | Glucocorticoid replacement therapy | Glucocorticoid receptor | Endocrinology | |
| standard glucocorticoid therapy | standard glucocorticoid therapy | phase 3 | glucocorticoid | glucocorticoid receptor | Immunology |
Therapeutic area mix
- Other · 2
- Endocrinology · 1
- Immunology · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bristol-Myers Squibb · 1 shared drug class
- ClinAmygate · 1 shared drug class
- F. Johannes Plate · 1 shared drug class
- First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
- First Affiliated Hospital of Zhejiang University · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Neurocrine UK Limited:
- Neurocrine UK Limited pipeline updates — RSS
- Neurocrine UK Limited pipeline updates — Atom
- Neurocrine UK Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Neurocrine UK Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurocrine-uk-limited. Accessed 2026-05-17.